← Back to Search

Senolytic Drug

Fisetin for COVID-19 (COVID-FIS Trial)

Phase 2
Waitlist Available
Led By Brandon P Verdoorn, MD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
CoV severity of moderate or less OR SpO2 ≥ 85% (on room air or ≤ 2 L of supplemental oxygen at time of enrollment)
Current nursing home resident
Must not have
Invasive fungal infection
Pregnancy (note that only post-menopausal women will be enrolled)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, day 2, 7, 10, 14, 17, 30, 90 and 180

Summary

This trial will test whether Fisetin can help prevent progression of the disease and reduce complications from coronavirus.

Who is the study for?
This trial is for nursing home residents aged 65 or older who have moderate or less severe COVID-19, confirmed by a PCR test within the last 10 days. Participants must be able to consent and have functioning major organs. Those with certain severe health conditions, participating in other COVID-19 treatment trials, or with allergies to Fisetin are excluded.
What is being tested?
The study is testing if Fisetin can prevent worsening of COVID-19 symptoms and reduce complications from excessive inflammation. It's a pilot study where participants will either receive Fisetin or a placebo without knowing which one they're getting.
What are the potential side effects?
While not specified here, potential side effects may include allergic reactions to Fisetin and typical drug-related issues such as gastrointestinal discomfort, headaches, dizziness, or skin rashes.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My COVID-19 symptoms are moderate or less, or my oxygen levels are 85% or higher.
Select...
I currently live in a nursing home.
Select...
I am a man or a post-menopausal woman aged 65 or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have an invasive fungal infection.
Select...
I am post-menopausal and not pregnant.
Select...
I am HIV positive.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, day 2, 7, 10, 14, 17, 30, 90 and 180
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, day 2, 7, 10, 14, 17, 30, 90 and 180 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in COVID-19 Severity

Side effects data

From 2023 Phase 1 & 2 trial • 75 Patients • NCT04210986
38%
Arthralgia
15%
Pain in Extremity
12%
Lab Findings
12%
Nausea
9%
Fatigue
9%
Back Pain
9%
Headache
6%
Muscle Cramp
6%
Flatulence
6%
Dry Mouth
6%
Rash Maculo-Papular
3%
Covid 19
3%
Bladder Perforation
3%
Neoplasms
3%
Rotator Cuff Injury
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
Fisetin

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Treatment GroupExperimental Treatment1 Intervention
Subjects will receive treatment drug (Fisetin)
Group II: Placebo GroupPlacebo Group1 Intervention
Subjects will receive placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Fisetin
2016
Completed Phase 2
~250

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,339 Previous Clinical Trials
3,062,125 Total Patients Enrolled
National Institute on Aging (NIA)NIH
1,788 Previous Clinical Trials
28,184,522 Total Patients Enrolled
Brandon P Verdoorn, MDPrincipal InvestigatorMayo Clinic

Media Library

Fisetin (Senolytic Drug) Clinical Trial Eligibility Overview. Trial Name: NCT04537299 — Phase 2
~6 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top